148 results
424B3
JAGX
Jaguar Health Inc
1 May 24
Prospectus supplement
5:22pm
refer to as preventive treatment of chemotherapy-induced overactive bowel (“CIOB”)-which includes symptoms such as chronic and/or episodic debilitating … in diarrhea-predominant irritable bowel syndrome (“IBS-D”) and being evaluated for chronic idiopathic/functional diarrhea. Crofelemer powder for oral solution
8-K
EX-99.1
6btdt rcx6jw
9 Apr 24
Jaguar Health Reports Approval of All Proposals at April 2024 Special Meeting of Stockholders
5:26pm
8-K
EX-99.1
0cjq8r 3rhn
21 Mar 24
Agreement terms to include payment of double-digit royalties to Jaguar on all Crofelemer products sold in the licensed territory
4:30pm
8-K
EX-99.1
5vl5mndo3z51da 3x
8 Nov 23
Jaguar Health Receives Additional 180-day Grace Period to Regain Compliance with Nasdaq’s Bid Price Rule
5:03pm
8-K
EX-99.1
frn5s4b rgpq3lb
14 Aug 23
Jaguar Health Reports Second Quarter 2023 Financial Results
9:05am
8-K
EX-99.1
cxnh zn4l0p6xglp8as
7 Jul 23
Jaguar Health Reports Approval of All Proposals at 2023 Annual Meeting of Stockholders
5:27pm
8-K
rxuv6qjodn0gxkfuzl
3 Jul 23
Entry into a Material Definitive Agreement
5:00pm
8-K
EX-99.1
jsb8i7
19 May 23
Departure of Directors or Certain Officers
5:00pm
8-K
EX-99.1
fqlp20zjvqdqftq
15 May 23
Jaguar Health Reports First Quarter 2023 Financial Results
8:33am
8-K
EX-99.1
vkemoam3rdit9cc
9 May 23
Jaguar Completes Enrollment in its Pivotal Phase 3 OnTarget Trial of Crofelemer for Prophylaxis of Cancer Therapy-Related Diarrhea
8:30am